Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has made significant strides in the development of innovative treatments for rare genetic diseases, positioning itself as a leader in the industry. With a strong operational presence in key regions, including Europe and Asia, Alnylam focuses on delivering transformative medicines that target the underlying causes of diseases. Its core products, such as ONPATTRO and GIVLAARI, are distinguished by their unique mechanism of action, offering patients new hope where traditional therapies have fallen short. Recognised for its commitment to scientific excellence, Alnylam has achieved numerous milestones, including the first-ever approval of an RNAi therapeutic, solidifying its market position as a trailblazer in the biopharmaceutical landscape.
DitchCarbon Score
How does Alnylam Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alnylam Pharmaceuticals's score of 66 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alnylam Pharmaceuticals's reported carbon emissions
In 2024, Alnylam Pharmaceuticals reported total carbon emissions of approximately 183,000,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 160,413,000 kg CO2e. The breakdown of emissions includes Scope 1 emissions at approximately 3,832,000 kg CO2e and Scope 2 emissions at about 8,018,000 kg CO2e (market-based). The company has set ambitious reduction targets, aiming to decrease its Scope 1 and Scope 2 emissions by 30% from 2020 levels by the year 2030. This commitment reflects a proactive approach to climate action, aligning with industry standards for sustainability and emissions reduction. In 2023, Alnylam's emissions were approximately 151,376,000 kg CO2e for Scope 3, with Scope 1 and Scope 2 emissions reported at about 3,546,000 kg CO2e and 9,918,000 kg CO2e, respectively. The trend indicates a growing awareness and response to climate change challenges within the pharmaceutical sector. Overall, Alnylam Pharmaceuticals is actively working towards reducing its carbon footprint while maintaining transparency in its emissions reporting and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 3,054,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,518,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 3,064,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alnylam Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
